NLTX - Neoleukin Therapeutics Inc Stock Price, Fair Value and News

15.10USD Delayed

Market Summary

USD15.10

Delayed

NLTX Stock Price

View Fullscreen

NLTX RSI Chart

NLTX Valuation

Market Cap

176.9M

Price/Earnings (Trailing)

-4.87

EV/EBITDA

-0.87

Price/Free Cashflow

-3.42

MarketCap/EBT

-4.87

NLTX Price/Sales (Trailing)

NLTX Profitability

Return on Equity

-19.52%

Return on Assets

-16.32%

Free Cashflow Yield

-29.26%

NLTX Fundamentals

NLTX Earnings

Earnings (TTM)

-36.3M

Earnings Growth (Yr)

-39.94%

Earnings Growth (Qtr)

-242.51%

Breaking Down NLTX Revenue

Last 7 days

287.6%

Last 30 days

297.7%

Last 90 days

266.9%

Trailing 12 Months

555.2%

How does NLTX drawdown profile look like?

NLTX Financial Health

Current Ratio

8.72

NLTX Investor Care

Shares Dilution (1Y)

10.32%

Diluted EPS (TTM)

-117.3

Tracking the Latest Insider Buys and Sells of Neoleukin Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 05, 2023	baker bros. advisors lp	acquired	-	-	592,650	-
Aug 17, 2023	baker bros. advisors lp	bought	115,617	0.692559	166,942	-
Aug 16, 2023	baker bros. advisors lp	bought	156,254	0.680548	229,600	-
Aug 15, 2023	baker bros. advisors lp	bought	1,191,620	0.630885	1,888,800	-
Aug 11, 2023	smith sean michael	sold	-818	0.6184	-1,323	interim cfo, prin acct off
Aug 10, 2023	smith sean michael	acquired	-	-	5,000	interim cfo, prin acct off
Apr 03, 2023	patel priti	sold	-2,607	0.6919	-3,769	-
Mar 31, 2023	patel priti	acquired	-	-	10,000	-
Feb 02, 2023	patel priti	sold	-8,587	0.5972	-14,380	chief medical officer
Feb 02, 2023	smith sean michael	sold	-1,980	0.5972	-3,316	principal accounting officer

Which funds bought or sold NLTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-796,081	-	-%
Feb 15, 2024	Farther Finance Advisors, LLC	sold off	-100	-790	-	-%
Feb 15, 2024	Nantahala Capital Management, LLC	sold off	-100	-1,185,000	-	-%
Feb 14, 2024	TWO SIGMA ADVISERS, LP	sold off	-100	-133,826	-	-%
Feb 14, 2024	Point72 Asset Management, L.P.	sold off	-100	-107,973	-	-%
Feb 14, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	sold off	-100	-1,224,500	-	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-135,114	-	-%
Feb 14, 2024	BAKER BROS. ADVISORS LP	sold off	-100	-4,824,580	-	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-149,136	-	-%

Are Funds Buying or Selling NLTX?

Are funds buying NLTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NLTX

No. of Funds

Unveiling Neoleukin Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	samsara biocapital, l.p.	9.99%	1,282,563	SC 13G
Feb 14, 2024	ecor1 capital, llc	9.99%	1,282,168	SC 13G
Feb 14, 2024	cormorant asset management, lp	1.21%	155,805	SC 13G
Feb 14, 2024	redmile group, llc	8.1%	1,050,304	SC 13G/A
Feb 14, 2024	lynx1 capital management lp	0.1%	46	SC 13G/A
Feb 14, 2024	great point partners llc	7.75%	994,229	SC 13G/A
Feb 14, 2024	janus henderson group plc	6.6%	841,688	SC 13G
Dec 27, 2023	great point partners llc	7.56%	969,229	SC 13G
Dec 22, 2023	redmile group, llc	9.9%	1,282,661	SC 13G/A
Dec 21, 2023	mcminn rachel	9.9%	1,273,351	SC 13D

Recent SEC filings of Neoleukin Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 25, 2024	8-K	Current Report
Apr 22, 2024	8-K	Current Report
Apr 02, 2024	8-K	Current Report
Mar 18, 2024	10-K	Annual Report
Mar 18, 2024	8-K	Current Report
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading

Peers (Alternatives to Neoleukin Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Neoleukin Therapeutics Inc News

Latest updates

Neoleukin Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	148.4%	223	90.00	94.00	98.00	109	127	137	149	163	176	187	200	211	222	145	153	147	70.00	74.00	75.00	78.00
Current Assets	150.8%	200	80.00	84.00	86.00	85.00	109	118	130	144	156	167	181	195	207	131	140	144	68.00	73.00	75.00	77.00
Cash Equivalents	487.5%	148	25.00	31.00	35.00	82.00	41.00	78.00	129	71.00	156	165	179	193	202	130	140	143	66.00	73.00	74.00	77.00
Net PPE	3448.3%	17.00	0.00	1.00	2.00	20.00	6.00	6.00	6.00	6.00	6.00	6.00	5.00	4.00	3.00	3.00	2.00	2.00	1.00	0.00	0.00	0.00
Liabilities	154.7%	37.00	14.00	14.00	17.00	11.00	21.00	20.00	19.00	20.00	21.00	20.00	21.00	19.00	21.00	17.00	16.00	5.00	3.00	1.00	4.00	5.00
Current Liabilities	340.8%	23.00	5.00	5.00	7.00	7.00	10.00	9.00	8.00	9.00	9.00	8.00	8.00	8.00	10.00	6.00	6.00	5.00	3.00	1.00	4.00	5.00
Shareholder's Equity	147.3%	186	75.00	80.00	81.00	94.00	106	117	130	143	155	167	179	191	200	129	137	142	67.00	72.00	72.00	73.00
Retained Earnings	60.3%	-187	-471	-467	-465	-150	-437	-424	-408	-393	-378	-362	-347	-332	-320	-317	-308	-299	-291	-232	-232	-230
Additional Paid-In Capital	-31.8%	373	547	547	547	5.00	543	541	539	536	533	530	527	524	521	447	445	441	358	305	304	303
Shares Outstanding	45.6%	13.00	9.00	9.00	9.00	9.00	11.00	11.00	11.00	8.00	11.00	11.00	11.00	8.00	-	-	-	-	-	-	-	-
Float	-	-	-	33.00	-	-	-	36.00	-	-	-	323	-	-	-	546	-	-	-	24.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-604.4%	-30,071	-4,269	-4,049	-13,033	-18,150	-9,289	-11,294	-14,091	-12,168	-8,756	-13,276	-13,358	-9,229	-112	-8,794	-6,440	-4,636	-6,532	-1,470	-2,756	-9,775
Share Based Compensation	-260.5%	-276	172	331	1,191	-5,537	2,031	2,312	2,446	3,009	3,210	2,918	2,420	2,229	1,688	1,022	683	666	5,151	788	1,078	837
Cashflow From Investing	1150.6%	16,956	-1,614	-411	10,706	65,371	-27,850	-39,299	-452	-396	-587	-1,191	-1,089	-653	-487	-972	-107	-782	-	-	-	-
Cashflow From Financing	9284400.0%	92,843	-1.00	-294	-66.00	66,388	-52.00	62.00	133	107	32.00	311	282	1,288	72,156	301	3,390	82,204	37.00	-2.00	-2.00	-2.00

NLTX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Operating expenses:

Research and development

$ 44,394

$ 47,505

General and administrative

11,189

9,012

Total operating expenses

55,583

56,517

Loss from operations

(55,583)

(56,517)

Other income (expense):

Interest income

2,951

1,337

Interest expense

(12)

(2)

Fair value allocated to bargain purchase gain

16,355

Other expense

(28)

(7)

Net loss

$ (36,317)

(55,189)

Class A Common Stock

Other income (expense):

Net loss

$ (55,189)

Earnings Per Share [Abstract]

Net income (loss) per share, basic (in dollars per share)

^[1]

$ (139.88)

Weighted-average shares outstanding used in computing net income (loss) per share, basic (in shares)

^[1]

394,533

Net income (loss) per share, diluted (in dollars per share)

^[1]

$ (139.88)

Weighted-average shares outstanding used in computing net income (loss) per share, diluted (in shares)

^[1]

394,533

Class B Common Stock

Other income (expense):

Net loss

$ 0

Earnings Per Share [Abstract]

Net income (loss) per share, basic (in dollars per share)

^[1]

$ 0

Weighted-average shares outstanding used in computing net income (loss) per share, basic (in shares)

^[1]

Net income (loss) per share, diluted (in dollars per share)

^[1]

$ 0

Weighted-average shares outstanding used in computing net income (loss) per share, diluted (in shares)

^[1]

[1]

On December 18, 2023, the Company completed its reverse merger, which among other things, resulted in Neurogene OpCo merging with and into a wholly owned subsidiary of Neoleukin Therapeutics, Inc. As the earnings per share information for the pre-merger period is not comparable to the earnings per share information for the post-merger period, the earnings per share information is being presented separately for these periods. See Note 3, Net Income (Loss) Per share, for additional information.

(a)Presents information for the pre-merger period for Class A common stock. The pre-merger period is January 1, 2023 through December 17, 2023 for the year ended December 31, 2023 and the full fiscal year ended December 31, 2022.

(b)Presents information for the pre-merger period for Class B common stock. The pre-merger period is January 1, 2023 through December 17, 2023 for the year ended December 31, 2023 and the full fiscal year ended December 31, 2022.

(c)Presents information for the post-merger period for common stock. The post-merger period is December 18, 2023 through December 31, 2023.

NLTX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 148,210	$ 82,021
Short-term investments	48,947	0
Prepaid expenses and other current assets	3,191	2,698
Total current assets	200,348	84,719
Property and equipment, net	17,174	20,115
Operating lease right-of-use assets	3,681	4,344
Finance lease right-of-use assets	98	87
Restricted cash	508	0
Other non-current assets	764	0
Total assets	222,573	109,265
Current liabilities:
Accounts payable	2,596	625
Accrued expenses and other current liabilities	17,495	5,324
Operating lease liabilities, current	2,559	678
Finance lease liabilities, current	42	24
Lease contingent value rights liability, current	281	0
Total current liabilities	22,973	6,651
Operating lease liabilities, non-current	12,302	3,921
Finance lease liabilities, non-current	65	66
Lease contingent value rights liability, non-current	1,006	0
Other liabilities	203	0
Total liabilities	36,549	10,638
Commitments and contingencies (Note 10)
Convertible preferred stock:
Total convertible preferred stock	0	244,366
Stockholders' equity (deficit)
Preferred stock, $0.000001 par value; 50,000,000 and 0 shares authorized as of December 31, 2023 and 2022, respectively; 0 shares issued and outstanding as of December 31, 2023 and 2022, respectively	0	0
Common stock, value, issued	0	0
Additional paid-in capital	373,178	5,098
Accumulated deficit	(187,154)	(150,837)
Total stockholders' equity (deficit)	186,024	(145,739)
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	222,573	109,265
Series A-1 Convertible Preferred Stock
Convertible preferred stock:
Total convertible preferred stock	0	34,414
Series A-2 Convertible Preferred Stock
Convertible preferred stock:
Total convertible preferred stock	0	28,675
Series B Convertible Preferred Stock
Convertible preferred stock:
Total convertible preferred stock	0	181,277
Class A Common Stock
Stockholders' equity (deficit)
Common stock, value, issued	0	0
Class B Common Stock
Stockholders' equity (deficit)
Common stock, value, issued	$ 0	$ 0

About Neoleukin Therapeutics Inc

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

CEO	Ms. Donna M. Cochener-Metcalfe J.D.
WEBSITE	neoleukin.com
INDUSTRY	Biotechnology
EMPLOYEES	7

Neoleukin Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Neoleukin Therapeutics Inc? What does NLTX stand for in stocks?

NLTX is the stock ticker symbol of Neoleukin Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Neoleukin Therapeutics Inc (NLTX)?

As of Thu Feb 29 2024, market cap of Neoleukin Therapeutics Inc is 176.86 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NLTX stock?

You can check NLTX's fair value in chart for subscribers.

What is the fair value of NLTX stock?

You can check NLTX's fair value in chart for subscribers. The fair value of Neoleukin Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Neoleukin Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NLTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Neoleukin Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether NLTX is over valued or under valued. Whether Neoleukin Therapeutics Inc is cheap or expensive depends on the assumptions which impact Neoleukin Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NLTX.